Universal Beteiligungs und Servicegesellschaft mbH Invests $798,000 in enVVeno Medical Corporation $NVNO

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in enVVeno Medical Corporation (NASDAQ:NVNO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 200,000 shares of the company’s stock, valued at approximately $798,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 1.04% of enVVeno Medical at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in NVNO. XTX Topco Ltd acquired a new stake in enVVeno Medical in the first quarter worth $80,000. Westside Investment Management Inc. grew its position in shares of enVVeno Medical by 7.9% during the second quarter. Westside Investment Management Inc. now owns 279,525 shares of the company’s stock worth $1,115,000 after acquiring an additional 20,475 shares during the last quarter. Creative Planning acquired a new stake in shares of enVVeno Medical in the 2nd quarter worth about $54,000. Finally, Geode Capital Management LLC lifted its position in enVVeno Medical by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after purchasing an additional 2,211 shares during the last quarter. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Price Performance

enVVeno Medical stock opened at $0.34 on Friday. enVVeno Medical Corporation has a 12-month low of $0.30 and a 12-month high of $5.62. The stock has a market capitalization of $6.87 million, a PE ratio of -0.28 and a beta of 0.86. The firm has a 50 day simple moving average of $0.71 and a 200-day simple moving average of $2.50.

enVVeno Medical (NASDAQ:NVNO) last announced its earnings results on Thursday, October 30th. The company reported ($0.23) EPS for the quarter. On average, analysts forecast that enVVeno Medical Corporation will post -1.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on NVNO. LADENBURG THALM/SH SH cut shares of enVVeno Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of enVVeno Medical in a report on Tuesday. Finally, Wall Street Zen cut enVVeno Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, enVVeno Medical has a consensus rating of “Reduce”.

enVVeno Medical Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).